NCT01966328View on ClinicalTrials.gov

A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Vitreomacular AttachmentVitreomacular TractionVitreomacular Adhesion
Interventions
DRUG

36% Resolvine Intravitreal Injection

36% Resolvine Intravitreal Injection

DRUG

9% Resolvine Intravitreal Injection

9% Resolvine Intravitreal Injection

Trial Locations (2)

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
collaborator

Kato Pharmaceuticals, Inc.

INDUSTRY

lead

Jeffrey S Heier

OTHER

NCT01966328 - A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment | Biotech Hunter | Biotech Hunter